Zacks Investment Research Downgrades Ocera Therapeutics, Inc. (OCRX) to Sell
Ocera Therapeutics, Inc. (NASDAQ:OCRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
Separately, HC Wainwright cut Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price target on the stock. in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Ocera Therapeutics presently has an average rating of “Hold” and a consensus price target of $1.69.
Ocera Therapeutics (NASDAQ OCRX) remained flat at $$1.71 during trading on Wednesday. 254,421 shares of the company’s stock were exchanged, compared to its average volume of 865,463. Ocera Therapeutics has a twelve month low of $0.52 and a twelve month high of $2.95.
An institutional investor recently raised its position in Ocera Therapeutics stock. Hikari Power Ltd lifted its position in shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 79.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 676,596 shares of the biopharmaceutical company’s stock after purchasing an additional 300,000 shares during the period. Hikari Power Ltd owned about 2.55% of Ocera Therapeutics worth $771,000 at the end of the most recent reporting period. Institutional investors own 20.22% of the company’s stock.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.